Press release
The Tapentadol Market to witness an innovative overhaul between 2017 - 2025
Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of December 2010 and by the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK on the fourth of February 2011. Tapentadol has been recognized as a step three analgesic on the World Health Organization (WHO) pain ladder. Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain. Tapentadol is available in the U.S.in extended release formulations as Nucynta ER from Janssen Pharmaceuticals. Nucynta contains the (R,R) stereoisomer, which is a weak isomer in terms of opioid activity.
To remain 'ahead' of your competitors, request for a samples@ https://www.persistencemarketresearch.com/samples/20656
Tapentadol is often used to ease pain which cannot be managed with other types of analgesics. Tapentadol formulation is provided in 100 mg (red/orange), 75 mg (orange) and 50 mg (yellow) tablets to be used once every five hours as needed to control pain. In addition, tapentadol can be used for controlling the pain of diabetic neuropathy when round the clock analgesic is required.
Furthermore, tapentadol can be used to treat chronic depression, although it is not approved for this treatment. However, tapentadol is known to have adverse side effects. Tapentadol may impair cognitive and physical abilities and should not be used when operating heavy machinery, especially during initial treatment. Dizziness, nausea, constipation and central nervous system (CNS) sedation are common side effects of tapentadol. Tapentadol can increase the risk of seizure and should be administered carefully to epileptic patients.
The growth in the analgesic market is expected to increase the consumption of tapentadol. In addition, rising demand for over the counter painkillers in emerging economies of Asia Pacific is expected to boost demand for tapentadol. However, government regulations, availability of substitutes and adverse effects of tapentadol could hamper the growth of the market.
North America is the largest market for tapentadol followed by Europe and Asia Pacific. The U.S is the largest country market in North America followed by Canada. Ageing population represents the key growth driver for the US market. Growth-wise, Asia-Pacific is projected to be the fastest growing market for tapentadol.
To connect with our sales representative- sales@persistencemarketresearch.com
China and India are expected to be the largest consumers of tapentadol in Asia Pacific due to growing population and rapid urbanization. Taiwan, Honk Kong, Japan, Republic of Korea, Malaysia and Indonesia are other major consumers of tapentadol in Asia Pacific. Increasing consumer awareness, better treatment and an increase in life expectancy is likely to propel future growth.
The market is dominated by large pharmaceutical companies with established brands. Some of the key players operating in this market are Johnson & Johnson Pharmaceutical Research & Development, L.L.C (U.S.), IPCA Laboratories Ltd (India), Lupin Laboratories Ltd (India), Ranbaxy Laboratories Ltd.(India), Aristo Pharmaceuticals Pvt Ltd (India), Cadila Pharmaceuticals Ltd (India), Tirupati Medicare Ltd (India) and Manus Aktteva Biopharma LLP (India) among others.
Companies are investing in research and development to develop new grades of Tapentadol. In addition, companies are using strategic acquisitions and mergers to remain competitive in market and increasing their presence in emerging economies of Asia Pacific and Latin America.
For in-depth competitive analysis, buy now@ https://www.persistencemarketresearch.com/checkout/20656
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
About us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Tapentadol Market to witness an innovative overhaul between 2017 - 2025 here
News-ID: 2634932 • Views: …
More Releases from Persistence Market Research
RFID Readers Market to Reach US$6.7 Billion by 2033, Growing at a 10.2% CAGR fro …
The global RFID readers market size is likely to be valued at US$3.4 billion in 2026 and is expected to reach US$6.7 billion by 2033, growing at a CAGR of 10.2% during the forecast period from 2026 to 2033. Market growth is being driven by increasing investments in automated identification, real-time asset tracking, inventory visibility, and connected supply chains across retail, logistics, manufacturing, healthcare, transportation, and other industries. RFID readers…
Semiconductor Advanced Substrate Market to Reach US$23 Billion by 2033 at 10.3% …
The global semiconductor advanced substrate market size is valued at US$11.6 billion in 2026 and is projected to reach US$23 billion by 2033, growing at a CAGR of 10.3% between 2026 and 2033. This exceptional growth is propelled by the explosive global demand for AI accelerators, high-performance computing (HPC) chips, GPUs, advanced processors, and next-generation data center infrastructure that require advanced packaging substrates with superior electrical performance, thermal management, signal…
Online Payment Fraud Detection Market to Reach US$20.3 Billion by 2033 at 13.4% …
The global Online Payment Fraud Detection market size is expected to be valued at US$8.4 billion in 2026 and is projected to reach US$20.3 billion by 2033, growing at a CAGR of 13.4% between 2026 and 2033. The market is expanding rapidly as digital payments, mobile commerce, online banking, and card-not-present transactions become increasingly prevalent worldwide. The growing sophistication of cybercriminals, rising financial losses associated with payment fraud, and increasing…
Biometric Palm Scanner Market to Reach US$8.6 Billion by 2033, Growing at a 7.9% …
The global biometric palm scanner market size is likely to be valued at US$5.1 billion in 2026 and is estimated to reach US$8.6 billion by 2033, growing at a CAGR of 7.9% during the forecast period from 2026 to 2033. Market growth is being supported by increasing demand for contactless authentication, rising concerns regarding identity security, growing adoption of biometric access control, and the need for reliable identification across healthcare,…
More Releases for Tapentadol
Tapentadol Market to Witness Huge Growth by 2031 - Johnson & Johnson Services, I …
DataM Intelligence has published a new research report on "Tapentadol Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/tapentadol-market
The…
The next 10 years to see the Tapentadol Market making green strides
Tapentadol Market
Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of…
Tapentadol Market Grows With Changing Consumer Preferences & New Opportunities
Market: Overview
Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of…
Tapentadol Market High Growth Rate by 2025
Global Tapentadol Market: Snapshot
The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is…
Middle East Tapentadol Market Forecast to 2025
Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and…
Tapentadol Market share research by applications and regions for 2017 - 2025
Global Tapentadol Market: Snapshot
The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is…
